Menu Search
Equities

Takeda Pharmaceutical Co Ltd

TKD:VIE

Takeda Pharmaceutical Co Ltd

Actions
  • Price (--)--
  • Today's Change--
  • Shares traded--
  • 1 Year change--
  • Beta--
--
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in JPYIncome statement in JPYView more

Year on year Takeda Pharmaceutical Co Ltd had net income fall -54.56% from 317.02bn to 144.07bn despite a 5.87% increase in revenues from 4.03tn to 4.26tn. An increase in the cost of goods sold as a percentage of sales from 30.89% to 33.46% was a component in the falling net income despite rising revenues.
Gross margin66.05%
Net profit margin6.38%
Operating margin9.80%
Return on assets1.97%
Return on equity4.15%
Return on investment2.35%
More ▼

Cash flow in JPYView more

In 2024, cash reserves at Takeda Pharmaceutical Co Ltd fell by 75.73bn. However, the company earned 716.34bn from its operations for a Cash Flow Margin of 16.80%. In addition the company used 463.86bn on investing activities and also paid 354.42bn in financing cash flows.
Cash flow per share660.33
Price/Cash flow per share6.40
Book value per share4,365.91
Tangible book value per share-1,267.98
More ▼

Balance sheet in JPYView more

Takeda Pharmaceutical Co Ltd has a Debt to Total Capital ratio of 42.19%, a lower figure than the previous year's 62.29%.
Current ratio1.28
Quick ratio0.7739
Total debt/total equity0.7299
Total debt/total capital0.4219
More ▼

Growth rates in JPY

SmartText is unavailable
Div yield(5 year avg)4.70%
Div growth rate (5 year)0.87%
Payout ratio (TTM)104.81%
EPS growth(5 years)-8.01
EPS (TTM) vs
TTM 1 year ago		49.16
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.